Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한운섭 | * |
dc.contributor.author | 김광호 | * |
dc.date.accessioned | 2016-08-28T11:08:10Z | - |
dc.date.available | 2016-08-28T11:08:10Z | - |
dc.date.issued | 1999 | * |
dc.identifier.issn | 0008-543X | * |
dc.identifier.other | OAK-152 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/218475 | - |
dc.description.abstract | BACKGROUND. Transforming growth factor-β1 (TGF-β1) acts as a potent inhibitor of cell growth and tumor progression but loss of this negative regulation can contribute to tumor development. Some studies have reported an association between disease progression and TGF-β1 expression in patients with colorectal carcinoma, but their results were not always consistent. METHODS. Serum levels of TGF-β1 were measured using an enzyme-linked immunoadsorbent assay in 121 consecutive patients with colorectal carcinoma and compared with TGF-β1 serum levels in 31 healthy volunteers. Serum levels of TGF-β1 also were measured in 50 patients who underwent curative surgical resection (part of the 121 preoperative patients) to compare their levels with preoperative serum levels of TGF-β1. RESULTS. Serum levels of TGF-β1 in patients with colorectal carcinoma (45 ± 15 ng/mL) (mean ± the standard deviation) were significantly higher than those in the healthy control group (32 ± 4 ng/mL) (P = 0.001). Serum levels of TGF-β1 increased with increasing tumor stage (P < 0.01). Serum levels of TGF-β1 were correlated significantly with depth of tumor invasion, lymph node metastasis, distant metastasis, and serum levels of carcinoembryonic antigen (CEA). Serum levels of TGF-β1 tended to increase with increasing CEA (correlation coefficient = 0.21; P < 0.05). The mean serum level of TGF-β1 in patients with colorectal carcinoma before surgery (45 ± 14 ng/mL) (n = 50) significantly decreased to 34 ± 7 ng/mL, which was within the normal range (32 ± 4 ng/mL), after curative surgical resection of the tumor (P = 0.0000). Serum levels of TGF- β1 after tumor resection decreased more significantly in patients with higher preoperative levels of TGF-β1 (from 53 ± 12 ng/mL to 36 ± 6 ng/mL) (n = 30). CONCLUSIONS. The results of the current study suggest that serum levels of TGF-β1 in colorectal carcinoma patients may be associated with disease progression and may be used as a biomarker in the management of colorectal carcinoma patients. The authors believe further studies with a large number of patients for a longer follow-up period are necessary to conclude whether serum levels of TGF-β1 carry significant clinical relevance. [See editorial on pages 517-9, this issue]. | * |
dc.language | English | * |
dc.title | Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 85 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 554 | * |
dc.relation.lastpage | 561 | * |
dc.relation.journaltitle | Cancer | * |
dc.identifier.doi | 10.1002/(SICI)1097-0142(19990201)85:3< | * |
dc.identifier.doi | 554::AID-CNCR6> | * |
dc.identifier.doi | 3.0.CO | * |
dc.identifier.doi | 2-X | * |
dc.identifier.wosid | WOS:000078390100006 | * |
dc.identifier.scopusid | 2-s2.0-0006335227 | * |
dc.author.google | Shim K.S. | * |
dc.author.google | Kim K.H. | * |
dc.author.google | Han W.S. | * |
dc.author.google | Park E.B. | * |
dc.contributor.scopusid | 한운섭(7401899962;24172227800) | * |
dc.contributor.scopusid | 김광호(57192983544) | * |
dc.date.modifydate | 20240118124654 | * |